Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,440,472
  • Shares Outstanding, K 1,253,528
  • Annual Sales, $ 22,449 M
  • Annual Income, $ 5,386 M
  • 60-Month Beta 0.51
  • Price/Sales 3.71
  • Price/Cash Flow 9.17
  • Price/Book 4.81
Trade GILD with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 2.02
  • Number of Estimates 11
  • High Estimate 2.25
  • Low Estimate 1.64
  • Prior Year 1.10
  • Growth Rate Est. (year over year) +83.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.56 +17.93%
on 12/31/20
68.38 -2.46%
on 01/26/21
+9.63 (+16.87%)
since 12/24/20
3-Month
56.56 +17.93%
on 12/31/20
68.38 -2.46%
on 01/26/21
+6.74 (+11.24%)
since 10/26/20
52-Week
56.56 +17.93%
on 12/31/20
85.97 -22.41%
on 03/19/20
+3.55 (+5.62%)
since 01/24/20

Most Recent Stories

More News
Will Eli Lilly (LLY) Beat Estimates This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) fourth-quarter sales.

GILD : 66.70 (-2.14%)
MRK : 80.25 (-1.11%)
INCY : 99.39 (-1.10%)
LLY : 212.72 (+0.17%)
Global Cellular Immunotherapy Markets 2020-2030 - Focus on Tumour-Infiltrating Lymphocyte, Engineered T Cell Receptor, Chimeric Antigen Receptor (CAR) T Cell, & Natural Killer (NK) Cell Therapy

, /PRNewswire/ -- The report has been added to offering.

GILD : 66.70 (-2.14%)
KITE : 179.99 (+0.11%)
NVS : 95.94 (-2.57%)
PFE : 37.31 (+0.08%)
Lilly's (LLY) Bamlanivimab Lowers COVID-19 Risk in Nursing Homes

Eli Lilly's (LLY) COVID-19 antibody drug bamlanivimab (LY-CoV555) reduces risk of contracting symptomatic COVID-19 infection by 80% at nursing homes in the United States.

REGN : 544.10 (-0.75%)
GILD : 66.70 (-2.14%)
INCY : 99.39 (-1.10%)
LLY : 212.72 (+0.17%)
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 4, after the market closes. At 4:30 p.m. Eastern...

GILD : 66.70 (-2.14%)
Worldwide HIV Drugs Industry to 2027 - Impact Analysis of COVID-19

, /PRNewswire/ -- The report has been added to offering.

GILD : 66.70 (-2.14%)
MRK : 80.25 (-1.11%)
PFE : 37.31 (+0.08%)
TEVA : 12.32 (-0.65%)
Gilead (GILD) Up 19% in the Past Month: What Lies Ahead?

Gilead (GILD) gains more than 19% in the past month and is poised to post a robust performance in the year ahead on strong HIV franchise.

NVO : 73.27 (+0.12%)
PFE : 37.31 (+0.08%)
GILD : 66.70 (-2.14%)
GSK : 39.24 (+0.82%)
Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

REGN : 544.10 (-0.75%)
GILD : 66.70 (-2.14%)
LLY : 212.72 (+0.17%)
ADMP : 1.6400 (-4.65%)
Global Antiretroviral Therapy Market Outlook to 2024, Featuring Company Profiles of Key Players Gilead Sciences, GSK, Roche Holding, Boehringer Ingelheim, Cipla and Abbvie

, /PRNewswire/ -- The report has been added to offering.

GILD : 66.70 (-2.14%)
Precision BioSciences' (DTIL) New Lymphoma Drug IND Gets FDA Nod

The FDA accepts Precision BioSciences' (DTIL) regulatory application to initiate a clinical study on its next-generation CD19 product candidate, PBCAR19B.

GILD : 66.70 (-2.14%)
LLY : 212.72 (+0.17%)
HALO : 48.65 (-0.31%)
DTIL : 12.40 (-6.70%)
Worldwide Pulmonary Arterial Hypertension Industry to 2025 - Featuring Gilead Sciences, United Therapeutics and Novartis International Among Others

The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report...

GILD : 66.70 (-2.14%)
UTHR : 164.85 (-2.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

3rd Resistance Point 69.69
2nd Resistance Point 69.03
1st Resistance Point 67.87
Last Price 66.70
1st Support Level 66.05
2nd Support Level 65.39
3rd Support Level 64.23

See More

52-Week High 85.97
Fibonacci 61.8% 74.74
Fibonacci 50% 71.26
Fibonacci 38.2% 67.79
Last Price 66.70
52-Week Low 56.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar